


Accepted Manuscript

Title: Going the distance: are we losing patients along the multiple myeloma treatment pathway?

Authors: Evangelos Terpos, Florence Suzan, Hartmut Goldschmidt



PII: S1040-8428(17)30478-X
DOI: <https://doi.org/10.1016/j.critrevonc.2018.03.021>
Reference: ONCH 2535

To appear in: *Critical Reviews in Oncology/Hematology*

Received date: 26-10-2017
Revised date: 21-3-2018
Accepted date: 25-3-2018

Please cite this article as: Terpos E, Suzan F, Goldschmidt H, Going the distance: are we losing patients along the multiple myeloma treatment pathway?, *Critical Reviews in Oncology / Hematology* (2018), <https://doi.org/10.1016/j.critrevonc.2018.03.021>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Going the distance: are we losing patients along the multiple myeloma treatment pathway?

Evangelos Terpos^{a,*}, Florence Suzan^b, Hartmut Goldschmidt^c

^a *Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece*

^b *Amgen (Europe) GmbH, Zug, Switzerland*

^c *Department of Internal Medicine V, University Hospital Heidelberg, and National Center for Tumor Diseases (NCT), Heidelberg, Germany*

[Word count: text, 2549; abstract, 150]

[Target journal: *Critical Reviews in Oncology Hematology*]

*** Corresponding author:** Evangelos Terpos, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Tel: +30 213 2162846. Fax: +30 210 3381511

E-mail address: eterpos@med.uoa.gr (E. Terpos).

Acknowledgements

Medical writing support was provided by Kim Allcott of Oxford PharmaGenesis, Oxford, UK.

Funding: Funding for the medical writing support was provided by Amgen (Europe) GmbH.

Download English Version:

<https://daneshyari.com/en/article/8733593>

Download Persian Version:

<https://daneshyari.com/article/8733593>

[Daneshyari.com](https://daneshyari.com)